330 related articles for article (PubMed ID: 32712461)
21. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?
Chadha AS; Liu G; Chen HC; Das P; Minsky BD; Mahmood U; Delclos ME; Suh Y; Sawakuchi GO; Beddar S; Katz MH; Fleming JB; Javle MM; Varadhachary GR; Wolff RA; Crane CH; Wang X; Thames H; Krishnan S
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):323-332. PubMed ID: 28068240
[TBL] [Abstract][Full Text] [Related]
22. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S
Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
Kong L; Zhang YW; Hu CS; Guo Y
Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
[TBL] [Abstract][Full Text] [Related]
24. Quality of Life Outcomes From a Phase 2 Trial of Short-Course Radiation Therapy Followed by FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer.
Khwaja SS; Roy A; Markovina S; Dewees TA; Hunt S; Tan B; Myerson RJ; Olsen JR; Parikh PJ
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1429-1438. PubMed ID: 27209506
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
26. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer.
Chadha AS; Skinner HD; Gunther JR; Munsell MF; Das P; Minsky BD; Delclos ME; Chatterjee D; Wang H; Clemons M; George G; Singh PK; Katz MH; Fleming JB; Javle MM; Wolff RA; Varadhachary GR; Crane CH; Krishnan S
PLoS One; 2016; 11(6):e0156910. PubMed ID: 27336466
[TBL] [Abstract][Full Text] [Related]
27. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
28. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
29. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M
J BUON; 2013; 18(2):385-90. PubMed ID: 23818350
[TBL] [Abstract][Full Text] [Related]
30. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
31. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer.
Sakr A; Elsherbiny M; Abdel Moneim R; Shaaban S; Aldaly M
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1717-1723. PubMed ID: 32592369
[TBL] [Abstract][Full Text] [Related]
33. Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study.
Yang B; Shan J; Feng Y; Dai N; Li M; Chen C; He S; Wang G; Xiao H; Li C; Wang D
Radiat Oncol; 2020 May; 15(1):94. PubMed ID: 32375814
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer.
Wo JY; Mamon HJ; Ferrone CR; Ryan DP; Blaszkowsky LS; Kwak EL; Tseng YD; Napolitano BN; Ancukiewicz M; Swanson RS; Lillemoe KD; Fernandez-del Castillo C; Hong TS
Radiother Oncol; 2014 Jan; 110(1):160-4. PubMed ID: 24231241
[TBL] [Abstract][Full Text] [Related]
35. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
36. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
37. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
38. The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer.
Herman JM; Narang AK; Griffith KA; Zalupski MM; Reese JB; Gearhart SL; Azad NS; Chan J; Olsen L; Efron JE; Lawrence TS; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e15-9. PubMed ID: 23058059
[TBL] [Abstract][Full Text] [Related]
39. Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study.
Oba A; Wu YHA; Lieu CH; Meguid C; Colborn KL; Beaty L; Al-Musawi MH; Davis SL; Leal AD; Purcell T; King G; Wooten ES; Fujiwara Y; Goodman KA; Schefter T; Karam SD; Gleisner AL; Ahrendt S; Leong S; Messersmith WA; Schulick RD; Del Chiaro M
Br J Surg; 2021 Aug; 108(8):976-982. PubMed ID: 34155509
[TBL] [Abstract][Full Text] [Related]
40. Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer.
Cella D; Butt Z; Kindler HL; Fuchs CS; Bray S; Barlev A; Oglesby A
Qual Life Res; 2013 Jun; 22(5):1105-12. PubMed ID: 22678353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
